Studies of the intestinal permeation mechanism are carried out using an Ussing chamber.

This device makes it possible to determine permeability, the active ingredient’s rate of transfer, the compound’s impact and physiological factors (composition of the gastro-intestinal environment).

  • Permeability studies, type of active-passive transition with increasing doses (3 Log), P influx measurement A-B (apical to basal).
  • Specific absorption sites  (duodenum, jejunum, ileum, colon).
  • Impact of P-glycoprotein: P efflux measurement B-A (basal to apical).
  • Impact of excipients.
  • Fraction absorbed by humans (F%).

Our protocols make it possible to study kinetics following application on the mucosal apical side (A) or the mesenteric serous side (B).

Our protocols also make it possible to precisely determine the permeability of the human intestine.

(Peff: effective permeability), based on the calibration of a series of remedies with variable permeability (providing the Peff and the absorption rate as a percentage, FA%).

  • Provides information to assess new preparations
  • Slow-release oral form
  • Immediate release form
  • Improves absorption



Ussing chamber picture


  • pKa, LogP, LogD
  • Study of the physiological solubility of active ingredients
  • Stability study in physiological environments
  • Determining the BCS biopharmaceutical classification
  • Effects of raw material particle size

Our Biogalenys standard range for determining human permeability